1.Clinical value of transthyretin from patients with early rheumatoid arthritis
Lei ZHAO ; Zhihua ZHANG ; Chunqiang BAI ; Fengyun JIANG ; Zhiqiang LIANG ; Xueyan WANG ; Changlai HAO
The Journal of Practical Medicine 2016;32(14):2337-2339
Objective To investigate the clinical value of transthyretin (TTR) from patients with early rheumatoid arthritis (ERA). Methods 58 patients with ERA , 34 patients with later RA (LRA) and 34 healthy control (HC) were included in the research. TTR was analyzed by ELISA, whose variance was analyzed. TTR density, disease activity score28 (DAS28) score and rheumatoid factor (RF) were tested, and their correlation with TTR was analyzed. Results Serum level of TTR with ERA significantly increased compared with that with LRA and HC (P < 0.05), no statistical significance with LRA group and HC. TTR level was no correlation with the number of swelling and tender joints, disease activity score 28, RF, ESR, CRP, anti-cyclic citrylinated peptide antibody and anti-keratin antibodies, hemoglobin, thrombocyte and albumin. Conclusion Serum level of TTR significantly increased with ERA patients, contributing to early diagnosis for RA.
2.A case of transcatheter closure of inferior vena cava type atrial septal defect with patent ductus arteriosus occlusion device guided by 3D printing technology.
Fan YANG ; Hong ZHENG ; Jianhua LYU ; Xinling YANG ; Yankun YANG ; Ying PANG ; Fang LIANG ; Gejun ZHANG ; Zhongying XU ; Shiliang JIANG ; Bin LYU ; Fengyun MENG ; Baojian HAO
Chinese Journal of Cardiology 2015;43(7):631-633
3.Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers
Xiaodan JIANG ; Yan JIANG ; Senbiao LUO ; Karthik SEKAR ; Clara Kai Ting KOH ; Amudha DEIVASIGAMANI ; Qingzhe DONG ; Niankai ZHANG ; Shenling LI ; Fengyun HAO ; Brian Kim Poh GOH ; London Lucien OOI ; Yu WANG ; Kam Man HUI
Cancer Research and Treatment 2021;53(4):944-961
Purpose:
NUF2 has been implicated in multiple cancers recently, suggesting NUF2 may play a role in the common tumorigenesis process. In this study, we aim to perform comprehensive meta-analysis of NUF2 expression in the cancer types included in the Cancer Genome Atlas (TCGA).
Materials and Methods:
RNA-sequencing data in 31 cancer types in the TCGA data and 11 independent datasets were used to examine NUF2 expression. Silencing NUF2 using targeting shRNAs in hepatocellular carcinoma (HCC) cell lines was used to evaluate NUF2’s role in HCC in vitro and in vivo.
Results:
NUF2 up-regulation is significantly observed in 23 out of the 31 cancer types in the TCGA datasets and validated in 13 major cancer types using 11 independent datasets. NUF2 overexpression was clinically important as high NUF2 was significantly associated with tumor stages in eight different cancers. High NUF2 was also associated with significantly poorer patient overall survival and disease-free survival in eight and six cancers, respectively. We proceeded to validate NUF2 overexpression and its negative association with overall survival at the protein level in an independent cohort of 40 HCC patients. Compared to the non-targeting controls, NUF2 knockdown cells showed significantly reduced ability to grow, migrate into a scratch wound and invade the 8 μm porous membrane in vitro. Moreover, NUF2 knockdown cells also formed significantly smaller tumors than control cells in mouse xenograft assays in vivo.
Conclusion
NUF2 up-regulation is a common feature of many cancers. The prognostic potential and functional impact of NUF2 up-regulation warrant further studies.